Condition: Primary Generalized Tonic-Clonic Seizures · Sponsor: Xenon Pharmaceuticals Inc.
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
This description comes directly from the study's public registry record.
Xenon Medical Affairs · 1-604-484-3300 · XenonCares@xenon-pharma.com
Always discuss trial participation with your own doctor first.
| University of Alabama - Strada Patient Care Center, Neurology | Mobile, Alabama, United States | Recruiting |
| Xenoscience | Phoenix, Arizona, United States | Recruiting |
| University of Arizona - Health Science Center | Tucson, Arizona, United States | Recruiting |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | Recruiting |
| Brain Science Research Institute | Los Angeles, California, United States | Recruiting |
| University of California, Irvine - Health Neurology Services | Orange, California, United States | Recruiting |
| University California, Davis Clinical & Translation Science Center Clinical Research (CCRC) | Sacramento, California, United States | Withdrawn |
| University of Colorado Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
| Mayo Clinic Florida | Jacksonville, Florida, United States | Recruiting |
| Serenity Research Center, LLC | Miami, Florida, United States | Recruiting |
| Research Institute of Orlando, LLC | Orlando, Florida, United States | Terminated |
| Panhandle Research and Medical Clinic | Pensacola, Florida, United States | Recruiting |
+ 126 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05667142